Antiandrogen withdrawal syndrome with nilutamide

Urology. 1997 Apr;49(4):632-4. doi: 10.1016/s0090-4295(96)00558-4.

Abstract

Antiandrogens are combined with medical or surgical castration to achieve total androgen blockade in metastatic prostate cancer. Discontinuation of antiandrogens at disease progression has been associated with prostate-specific antigen (PSA) decrease, symptom improvement, and occasionally objective tumor regression. Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported. Improvement in urinary symptoms, bone pain and, in one, disappearance of para-aortic lymphadenopathy paralleled the PSA decrease. The duration of the withdrawal response of 6 months was comparable to those reported with discontinuation of flutamide.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists*
  • Bone Neoplasms / blood
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Humans
  • Imidazoles*
  • Imidazolidines*
  • Male
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Substance Withdrawal Syndrome

Substances

  • Androgen Antagonists
  • Imidazoles
  • Imidazolidines
  • nilutamide
  • Prostate-Specific Antigen